Nico Gagelmann (@nicogagelmann) 's Twitter Profile
Nico Gagelmann

@nicogagelmann

Hematology. Medicine. Science. Train. Think. Implement an integral actuality.

ID: 1054759355512438786

calendar_today23-10-2018 15:40:01

14,14K Tweet

47,47K Followers

696 Following

Gonzalo Bentolila (@gonzalobentoli1) 's Twitter Profile Photo

What a dream team at #GATMO2025! Nico Gagelmann, Carmelo Gurnari, Queralt Salas y Mi Kwon โ€” thank you for lighting up the room with your brilliance, kindness, and energy! We learned, laughed, and felt truly inspired. Hope to see you all back soon! ๐Ÿงฌโœจ๐ŸŒŽโค๏ธ #NextGenHematology

What a dream team at #GATMO2025!
<a href="/NicoGagelmann/">Nico Gagelmann</a>, <a href="/CarmeloGurnari/">Carmelo Gurnari</a>, <a href="/QueraltSalas/">Queralt Salas</a> y Mi Kwon โ€” thank you for lighting up the room with your brilliance, kindness, and energy!
We learned, laughed, and felt truly inspired.
Hope to see you all back soon!
๐Ÿงฌโœจ๐ŸŒŽโค๏ธ #NextGenHematology
Nico Gagelmann (@nicogagelmann) 's Twitter Profile Photo

Early-Phase Trials in Journal of Clinical Oncology on aspects of what constitutes high-quality early-phase trials with the goal of providing guidance for future JCO submissions. ascopubs.org/doi/10.1200/JCโ€ฆ

Early-Phase Trials in <a href="/JCO_ASCO/">Journal of Clinical Oncology</a> on aspects of what constitutes high-quality early-phase trials with the goal of providing guidance for future JCO submissions.
ascopubs.org/doi/10.1200/JCโ€ฆ
๐—ก๐—ถ๐—ต๐—ฎ๐—ฟ ๐——๐—ฒ๐˜€๐—ฎ๐—ถ MD, DM (@nihardesai89) 's Twitter Profile Photo

Out now in Blood Journal, Lu et al ๐Ÿ™Œ๐Ÿฝ Phase IIb Ven/Dec vs Intensive chemo (7&3) in younger adults with AML ๐Ÿ’ช๐Ÿฝ 1ยฐ end point: CRc after induction โžก๏ธCRc 89% vs 79%, non inf p=0.002 ๐Ÿ’ช๐Ÿฝ โžก๏ธVen/Dec better tolerated ๐Ÿ™Œ๐Ÿฝ #MedTwitter ashpublications.org/blood/article/โ€ฆ

Out now in <a href="/BloodJournal/">Blood Journal</a>, Lu et al ๐Ÿ™Œ๐Ÿฝ

Phase IIb

Ven/Dec vs Intensive chemo (7&amp;3) in younger adults with AML ๐Ÿ’ช๐Ÿฝ

1ยฐ end point: CRc after induction 

โžก๏ธCRc 89% vs 79%, non inf p=0.002 ๐Ÿ’ช๐Ÿฝ
โžก๏ธVen/Dec better tolerated ๐Ÿ™Œ๐Ÿฝ

#MedTwitter 

ashpublications.org/blood/article/โ€ฆ
Journal of Clinical Oncology (@jco_asco) 's Twitter Profile Photo

โ€ผ๏ธ #ASCO25 simultaneous publication by Mazyar Shadman, MD MPH et al:โ€ฏ Zanubrutinib and Venetoclax for Patients With Treatment-Naรฏve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results: brnw.ch/21wT3Ph

โ€ผ๏ธ #ASCO25 simultaneous publication by <a href="/mshadman/">Mazyar Shadman, MD MPH</a> et al:โ€ฏ 

Zanubrutinib and Venetoclax for Patients With Treatment-Naรฏve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results: brnw.ch/21wT3Ph
Gonzalo Bentolila (@gonzalobentoli1) 's Twitter Profile Photo

โœจ Thank you to everyone who joined #GATMO2025! ๐Ÿ™Œ With 254 in-person and 53 virtual participants from over 15 countries ๐ŸŒ, we proudly met our goals of networking and inspiring the next generation ๐Ÿ’ช๐Ÿง  Feeling very happy and grateful! โค๏ธ ๐Ÿ”— gatmo.sahonline.com.ar

โœจ Thank you to everyone who joined #GATMO2025! ๐Ÿ™Œ
With 254 in-person and 53 virtual participants from over 15 countries ๐ŸŒ, we proudly met our goals of networking and inspiring the next generation ๐Ÿ’ช๐Ÿง 
Feeling very happy and grateful! โค๏ธ
๐Ÿ”— gatmo.sahonline.com.ar
๐—ก๐—ถ๐—ต๐—ฎ๐—ฟ ๐——๐—ฒ๐˜€๐—ฎ๐—ถ MD, DM (@nihardesai89) 's Twitter Profile Photo

Arjun D. Law has been so much more than a mentor, more like a (tor)mentor! From medicine to life itself, he has taught me everything with humour and ruthless honesty. Grateful. Traumatised. Wouldnโ€™t change a thing. โค๏ธ

<a href="/Haemophage/">Arjun D. Law</a> has been so much more than a mentor, more like a (tor)mentor!

From medicine to life itself, he has taught me everything with humour and ruthless honesty.

Grateful. Traumatised. Wouldnโ€™t change a thing. โค๏ธ
Nico Gagelmann (@nicogagelmann) 's Twitter Profile Photo

๐ŸŽ‰Finally out๐ŸŽ‰ Our study showed value of low dose splenic irradiation and transplantation as part of a curative approach in myelofibrosis with refractory splenomegaly: - significant spleen size reduction - excellent engraftment #mpnsm Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-โ€ฆ

๐ŸŽ‰Finally out๐ŸŽ‰

Our study showed value of low dose splenic irradiation and transplantation as part of a curative approach in myelofibrosis with refractory splenomegaly:
- significant spleen size reduction
- excellent engraftment

#mpnsm <a href="/ASTCT_Journal/">Transplantation and Cellular Therapy Journal</a> 
astctjournal.org/article/S2666-โ€ฆ
Nico Gagelmann (@nicogagelmann) 's Twitter Profile Photo

๐ŸŽ‰Finally out๐ŸŽ‰ Daratumumab for post-transplant pure red cell aplasia: study and practical considerations from The EBMT Now in Blood Cancer Journal nature.com/articles/s4140โ€ฆ

๐ŸŽ‰Finally out๐ŸŽ‰

Daratumumab for post-transplant pure red cell aplasia: study and practical considerations from <a href="/TheEBMT/">The EBMT</a>

Now in <a href="/BloodCancerJnl/">Blood Cancer Journal</a> 
nature.com/articles/s4140โ€ฆ
Jonathan Friedberg (@drjfriedberg) 's Twitter Profile Photo

Timely tour de force review on Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinaseโ€“Targeted Approaches | Journal of Clinical Oncology Toby Eyre ascopubs.org/doi/full/10.12โ€ฆ